William Richard White Sells 75,159 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 75,159 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $27.21, for a total value of $2,045,076.39. Following the transaction, the chief financial officer now owns 41,791 shares of the company’s stock, valued at approximately $1,137,133.11. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

William Richard White also recently made the following trade(s):

• On Wednesday, July 24th, William Richard White sold 139,083 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.98, for a total transaction of $3,752,459.34.
• On Tuesday, July 16th, William Richard White sold 34,811 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.04, for a total transaction of $976,100.44.
• On Tuesday, June 11th, William Richard White sold 2,831 shares of Akero Therapeutics stock. The shares were sold at an average price of $22.64, for a total transaction of $64,093.84.

Akero Therapeutics Stock Performance

Akero Therapeutics stock traded up $0.26 during trading hours on Thursday, hitting $26.89. 360,848 shares of the stock traded hands, compared to its average volume of 973,676. The firm’s 50 day moving average price is $25.11 and its 200-day moving average price is $23.66. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -8.40 and a beta of -0.28. Akero Therapeutics, Inc. has a 1 year low of $11.25 and a 1 year high of $53.77.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities analysts expect that Akero Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Institutional Trading of Akero Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in shares of Akero Therapeutics in the 4th quarter valued at about $28,000. Russell Investments Group Ltd. grew its stake in Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares during the period. Quarry LP increased its holdings in Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after acquiring an additional 500 shares in the last quarter. Strs Ohio lifted its holdings in Akero Therapeutics by 100.0% during the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $75,000.

Analyst Upgrades and Downgrades

AKRO has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Wolfe Research assumed coverage on shares of Akero Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating for the company. Canaccord Genuity Group dropped their target price on Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Monday, August 12th. Finally, Evercore ISI reduced their price objective on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research note on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Akero Therapeutics has an average rating of “Moderate Buy” and an average target price of $41.13.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.